Results 21 to 30 of about 8,187 (238)

Purple-Colored Urine Induced by Cefiderocol: A Case Report and Comprehensive Literature Review

open access: yesBacteria
Background: Purple urine discoloration, known as purple urine bag syndrome (PUBS), has various etiologies ranging from benign to serious conditions. We present a case of cefiderocol-induced PUBS and review the literature. Methods: A 56-year-old bedridden
Elie Bou Sanayeh   +3 more
doaj   +2 more sources

Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine [PDF]

open access: yesAntibiotics, 2023
Cefiderocol susceptibility testing represents a major challenge for clinical microbiology. Although disc diffusion showed robustness to test cefiderocol susceptibility, large areas of technical uncertainty (ATU) are reported by current EUCAST breakpoints.
Gabriele Bianco   +5 more
doaj   +2 more sources

Clinical experience of cefiderocol [PDF]

open access: yesRevista Española de Quimioterapia, 2022
Infections by antibiotic-resistant microorganisms could be considered a “stealth pandemic” that we fight daily in most hospitals. Some estimates suggest that today 700,000 deaths per year can be attributed to antimicrobial resistance. By the year 2050, it is estimated that this will increase to ten million deaths per year as a result of infections by ...
Fariñas Álvarez, María del Carmen   +1 more
openaire   +4 more sources

In vitro pharmacokinetics of cefiderocol alone and in combination with antibiotics against Achromobacter spp. and Stenotrophomonas maltophilia species

open access: yesJournal of Global Antimicrobial Resistance
AIM: The point of this study was to compare and to contrast how well cefiderocol worked against a group of Achromobacter spp. and Stenotrophomonas maltophilia isolates in-vitro, both by itself and when mixed with other antibiotics.
Gokce Konyaoglu   +5 more
doaj   +2 more sources

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms

open access: yesbioRxiv
Acinetobacter baumannii is a nosocomial pathogen notorious for rapidly acquiring resistance to nearly all antibiotics, including last-line agents.
Justin Halim   +8 more
semanticscholar   +2 more sources

Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections

open access: yesJAC-Antimicrobial Resistance
Background Cefiderocol exhibits potent in vitro activity against carbapenem-resistant Acinetobacter baumannii (CRAb), but this activity has not consistently translated to improved outcomes among patients.
R. K. Shields   +12 more
semanticscholar   +2 more sources

Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa

open access: yesHeliyon
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic
Igor Chebotar   +3 more
doaj   +2 more sources

Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review [PDF]

open access: yesInfectious Disease and Therapy
The treatment of Stenotrophomonas maltophilia bloodstream infections (BSI) remains challenging due to the organism's intrinsic multidrug resistance and the potential side effects of commonly used first-line antibiotics. Here, we describe four cases of S.
A. Vena   +25 more
semanticscholar   +2 more sources

Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol

open access: yesbioRxiv
Introduction Klebsiella pneumoniae carbapenemase (KPC) is one of the most widespread carbapenemases, with over 242 variants identified. Some, like KPC-33 (D179Y), resist both ceftazidime-avibactam (CZA) and cefiderocol but show only a moderate ...
Sidonie Hanna   +7 more
semanticscholar   +2 more sources

Cefiderocol nonsusceptibility among carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: data from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
We evaluated cefiderocol activity against carbapenem-resistant Pseudomonas aeruginosa (CRPA) and carbapenem-resistant Acinetobacter baumannii (CRAB), characterized the β-lactamase gene profiles of cefiderocol-nonsusceptible CRPA by metallo-β-lactamase ...
Po-Wei Chiu   +6 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy